J&J, Roche, Celgene and others power new cancer-drug wave

Tracy Staton In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. ...

Merck wins FDA approval for a once-vaunted cardio drug

Damian Garde Merck picked up FDA approval for the clot-busting cardio drug vorapaxar, a treatment once billed as a potential warfarin successor before running into some alarming safety ...

Can payers get to ‘rational’ hep C drug prices without a price war?

Tracy Staton Payers worried about hepatitis C drug prices have been counting on impending price competition to save them money. The idea is that, once Merck, AbbVie and Bristol-Myers ...

AstraZeneca rushes immuno-oncology star into PhIII lung cancer study

John Carroll Anxious to fight off Pfizer’s $ 106 billion marriage proposal, AstraZeneca’s research team has rushed its high-profile immuno-oncology drug into a late-stage ...

Naurex picks up $25M to get its depression drugs through PhII

Damian Garde Evanston, IL's Naurex nailed down another $ 25 million in venture funding to accelerate its two-pronged depression program, posting positive mid-stage results for ...

Cancer-drug market zooms toward $100B, thanks to costly targeted therapies

Tracy Staton What's a blockbuster market worth? In the case of cancer treatments, the answer will soon be $ 100 billion. According to a new study by the IMS Institute for Healthcare ...

Endo appoints former Bausch + Lomb exec to head corporate strategy

Alok Saboo FierceBiotech News

Germany says it is unclear whether Gilead’s Sovaldi prevents liver cancer

Eric Palmer Gilead Sciences has argued that its hep C blockbuster Sovaldi will save healthcare payers money by preventing transplants for patients who develop cancer. But now the U.S. ...

Vertex, once king of hep C category, bows out as new drugs eclipse Incivek

Eric Palmer Biotech Vertex has pulled the plug on work in the hepatitis C arena, an area it was expected to dominate with its Incivek until Gilead Sciences redefined the category with ...

Acorda’s seizure spray gets the FDA blow-off

Damian Garde The FDA has rejected Acorda Therapeutics' nasal spray for epilepsy, throwing a wrench in the biotech's plan for a quick trip to the market with its orphan drug. FierceBiotech ...

GlaxoSmithKline picks up FDA approval for its latest COPD contender

Damian Garde Adding to its string of respiratory victories, GlaxoSmithKline won an FDA nod for Incruse Ellipta, a once-daily COPD inhaler. FierceBiotech News

Teva could jump into pharma’s deal frenzy, CEO says

Carly Helfand A few months ago, Teva CFO Eyal Desheh told the J.P. Morgan Healthcare Conference that armed with a new incoming CEO and a reasonable debt level, the Israeli company was ...
Page 3 of 41234
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS